Page 5 - Us Markets

Stock Market Highlights, May 30: Sensex drops 617 pts, gives up 74K; Nifty below 22,500

Stock Market Highlights on May 30: In the broader markets, the BSE MidCap, and SmallCap indices fell over 1 per cent each

Stock Market Highlights, May 28: Sensex falls 220 pts after listless session; SmallCaps bleed

Stock Market Highlights on May 28, 2024: The losses were steeper in the broader markets where the BSE MidCap fell 0.63 per cent, and the BSE SmallCap slipped 1.09 per cent

Nvidia's Q1 result preview: Know street expectation, stock strategy here

Analysts are eyeing impressive figures, with the street anticipating earnings of $13.2 billion, translating to $5.62 per share, alongside projected revenue of $24.6 billion in the quarter

Akshaya Tritiya, May 10: Silver prices up despite hawkish Fed; buy the dips

Weak job data bolstered the speculation that the weakening economy would force the US Federal Reserve to cut rates

G42 made secret pact with US to divest from China before Microsoft deal

In exchange for the Chinese divestment, G42 was assured that it would have continued access to US technology that powers AI applications, one of the people said

Average long-term US mortgage rate edges closer to 7%, highest since March

The average long-term U.S. mortgage rate rose to its highest level in five weeks, a setback for prospective homebuyers during what's traditionally the busiest time of the year for home sales. The average rate on a 30-year mortgage rose to 6.88% from 6.82% last week, mortgage buyer Freddie Mac said Thursday. A year ago, the rate averaged 6.27%. When mortgage rates rise, they can add hundreds of dollars a month in costs for borrowers, limiting how much they can afford at a time when the U.S. housing market remains constrained by relatively few homes for sale and rising home prices. Rates have been mostly drifting higher in recent weeks as stronger-than-expected reports on employment and inflation have stoked doubt among bond investors over how soon the Federal Reserve will move to lower its benchmark interest rate. The central bank has signaled that it expects to cut its short-term rate three times this year once it sees more evidence of cooling inflation. On Wednesday, Treasury yiel

Are the stock markets prepared for a delay in interest rate cut?

As regards rate cuts, analysts expect the global central banks, especially in Asia, to follow the Fed in rate cutting cycle

Nasdaq resolves glitch that impacted trading; downtime lasted around 2 hrs

The Nasdaq is home to thousands of stocks, including those of iPhone maker Apple, electric vehicle-maker Tesla and semiconductor powerhouse Nvidia

Goldman Sachs ups stock buyback forecast for companies in S&P 500 index

The Wall Street brokerage had earlier expected a 4% annual rise in companies buying back their own shares, against a 14% fall last year

Equity investors make best returns amid falling interest rates: UBS

Based on free-float market capitalisation in the FTSE All-World index, which spans the investable universe for a global investor, the US market accounts for a staggering 60.5 per cent of total value

85% of small US businesses show optimism for growth in 2024: Survey

While it seems increasingly unlikely the US economy is headed for recession, small businesses still face headwinds like higher costs and difficulty retaining qualified workers. But owners say they're optimistic as 2024 gets underway, according to a new survey from American Express. Eighty-five percent of all small businesses surveyed said they were satisfied with the success of their business, and 86 per cent said they achieved their 2023 business goals. In August 2023, by contrast, 80 per cent of all small businesses surveyed said their long-term financial confidence was being negatively impacted by the economy. Even in uncertain economic conditions, small businesses continue to demonstrate resiliency and dedication, said Gina Taylor, executive vice president and general manager of American Express' small business products and Business Blueprint. Our latest data shows small businesses see a positive 2024 ahead and they're taking steps, including hiring, and implementing new tools,

Domestic business, US launches to drive gains for Zydus Lifesciences

Q3 results better than estimates on the back of higher gross margins

India cuts import duty to 5-10% on some fresh, processed food items

The tariff cut is unlikely to hurt the domestic market since this is an exclusive market that caters to a limited segment that wants to buy international products

Cipla eyes acquisitions, inorganic partnerships in US, European markets

Drug major Cipla is eyeing acquisitions and inorganic partnerships in the US market while consolidating its presence across segments in the domestic market. The Mumbai-based company is also looking to improve the top line in Europe and margin expansion in South Africa. "Product launches through delisting strategy and as well as inorganic partnerships and acquisitions will remain one of our key priorities for the US market," Cipla Global Chief Financial Officer Ashish Adukia said in an analyst call. The drug maker would also focus on commercial execution of existing portfolios and resolution of USFDA observations, he added. In the South African market, Cipla would build on its performance aided by growth in private and select tender business with greater emphasis on margin expansion, Adukia stated. "In emerging markets and Europe, top priority is to improve top line while margins are maintained at sustainable levels," he said. As per the yearly trend, the fourth quarter will have

Equity, money markets in the US remain polarised, says Chris Wood

Another key development in the US, that the global equity markets would eye over the next few months, is how the political landscape shapes up ahead of the presidential elections

Ashok Soota-led Happiest Minds eyes strong momentum from India biz

Manufacturing and banking, financial services and insurance (BFSI) together contribute about 26 per cent to the total revenues

Kent RO Systems to enter US market, targets Rs 2,000 cr turnover in 3 yrs

Home-grown water purifier maker Kent RO System aims to enter the US market next fiscal and expand its appliances portfolio as it targets a Rs 2,000 crore turnover in the next three years, its Chairman & Managing Director Mahesh Gupta said. Besides, Kent RO Systems, which has invested Rs 500 crore on expansion in the last three years, has plans to invest Rs 300 crore more to set up a new fan manufacturing unit at Yamuna Expressway in Uttar Pradesh, he said. The company, earlier known for water purifiers, is diversifying its portfolio and enhancing its presence in the appliances segment, especially small kitchen appliances. Gupta expects new categories to contribute half of the revenue in coming years. Over its foray into the US market, Gupta said Kent RO System has entered into a brand licensing agreement with Black & Decker. As part of that, it will manufacture and ship its range of water purifiers under the brand name of the Maryland US-based manufacturer. "We will be going .

BlackRock quarterly profit rises on strong assets under management

Hopes of a soft landing - a scenario where inflation eases without a sharp rise in unemployment - have cheered markets in recent months

Leading domestic pharma Companies to see 9-11% revenue growth in FY24

Revenue of 25 leading domestic pharmaceutical companies is expected to grow 9-11 per cent in the current fiscal year, as per Icra. The projected revenue growth in 2023-24 will be primarily supported by 11-13 per cent expansion in the US market and 7-9 per cent growth in the domestic market, while revenues from the European market and emerging markets are expected to rise 11-13 per cent and 13-15 per cent, respectively, the rating agency said in a statement. "Icra expects the revenues of a sample set of 25 Indian pharmaceutical companies (which account for 60 per cent of the overall revenues of the Indian pharmaceutical industry) to expand by 9-11 per cent in FY24, post a year-on-year growth of 10 per cent in FY23," it noted. Icra said it foresees research and development expenses for its sample set of companies to stabilise at 6.5-7 per cent of their revenues as they will optimise spending, focusing more on complex molecules and specialty products against plain vanilla generics. Th

Alembic Pharmaceuticals clinches eight USFDA approvals in Q3 FY24

The same day, Alembic Pharma's share price rose to 3.55 per cent, ending the day's trade at Rs 792 apiece on the BSE